The Molecular Basis of Resistance to the Antiproliferative Effect of EGFR Inhibition in Human Glioblastoma Multiforme Cell Lines

The Molecular Basis of Resistance to the Antiproliferative Effect of EGFR Inhibition in Human Glioblastoma Multiforme Cell Lines
Author: Georg Karpel-Massler
Publisher:
Total Pages:
Release: 2011
Genre:
ISBN: 9789533075884


Download The Molecular Basis of Resistance to the Antiproliferative Effect of EGFR Inhibition in Human Glioblastoma Multiforme Cell Lines Book in PDF, Epub and Kindle


The Molecular Basis of Resistance to the Antiproliferative Effect of EGFR Inhibition in Human Glioblastoma Multiforme Cell Lines
Language: en
Pages:
Glioblastoma Resistance to Chemotherapy: Molecular Mechanisms and Innovative Reversal Strategies
Language: en
Pages: 832
Authors: Ramasamy Paulmurugan
Categories: Science
Type: BOOK - Published: 2021-06-25 - Publisher: Academic Press

GET EBOOK

Glioblastoma Resistance to Chemotherapy: Molecular Mechanisms and Innovative Reversal Strategies brings current knowledge from an international team of experts
PDGFR[beta] Expression as a Mode of Resistance to EGFR Inhibition in Glioblastoma
Language: en
Pages: 65
Authors: David Akhavan
Categories:
Type: BOOK - Published: 2012 - Publisher:

GET EBOOK

Glioblastoma is the most common and most aggressive form of malignant primary brain tumor in adults. The epidermal growth factor receptor (EGFR) is a compelling
Tumors of the Central Nervous System, Volume 1
Language: en
Pages: 436
Authors: M. A. Hayat
Categories: Medical
Type: BOOK - Published: 2011-03-23 - Publisher: Springer Science & Business Media

GET EBOOK

The most recent developments in diagnostic and therapeutic aspects of Gliomas (Glioblastoma) in the brain are presented. The importance of personalized medicine
Preclinical Development of Dual EGFR/DNA Targeting Agent in Glioblastoma
Language: en
Pages:
Authors: Zeinab Sharifi
Categories:
Type: BOOK - Published: 2019 - Publisher:

GET EBOOK

"Glioblastoma (GBM) is one of the most frequent, invasive and devastating primary brain tumors with a median overall survival rate of about 15 months despite ag